PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
11.79%
Revenue growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.13%. Joel Greenblatt would investigate if growth quality matches quantity.
73.20%
Cost growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.90%. Jim Chanos would check for structural cost disadvantages.
-46.43%
Gross profit decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive position.
-52.08%
Margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive position.
88.66%
R&D change of 88.66% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
27.85%
G&A change of 27.85% versus flat Drug Manufacturers - Specialty & Generic overhead. Walter Schloss would verify efficiency.
-3.10%
Marketing expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive implications.
-2087.13%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
17.64%
Operating expenses growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.35%. Jim Chanos would check for waste.
49.74%
Total costs growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.95%. Jim Chanos would check for waste.
-14.42%
Interest expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
11.96%
D&A growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.81%. Jim Chanos would check for overinvestment.
11.92%
EBITDA change of 11.92% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
-295.55%
EBITDA margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-309.91%
Operating income decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-287.78%
Operating margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-369.08%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is -2.19%. Seth Klarman would investigate advantages.
-3600.20%
Pre-tax income decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-3210.05%
Pre-tax margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-1523.43%
Tax expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
-2284.85%
Net income decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-2033.39%
Net margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-2260.25%
EPS decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-2260.25%
Diluted EPS decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
0.61%
Share count reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.05%. Jim Chanos would check for issues.
0.61%
Diluted share reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.04%. Jim Chanos would check for issues.